Oxygenta Pharmaceutical Hits 52-Week High, Outperforms Sector and Sensex

Oct 28 2024 10:35 AM IST
share
Share Via
Oxygenta Pharmaceutical, a microcap company in the pharmaceuticals and drugs industry, has reached a new milestone with its stock price hitting a 52-week high of Rs. 108.64 on October 28, 2024. The stock has outperformed its sector and consistently traded at its opening price, with a remarkable 80.11% increase in the past 21 days. With a Hold rating from MarketsMojo and a strong 1-year performance of 323.71%, the company shows potential for growth in the market.


Oxygenta Pharmaceutical, a microcap company in the pharmaceuticals and drugs industry, has recently reached a new milestone. On October 28, 2024, the company's stock price hit a 52-week high of Rs. 108.64. This news has caught the attention of investors and market analysts alike.

According to MarketsMOJO, a leading financial research and analysis firm, the stock has been given a "Hold" rating. This means that while the stock is performing well, it is not recommended for immediate purchase or sale.

In terms of performance, Oxygenta Pharmaceutical has outperformed its sector by 2.61% today. The stock has been on a winning streak for the past 21 days, with a remarkable 80.11% increase in its value during this period. It also opened with a gain of 2% today and reached an intraday high of Rs. 108.64.

One notable aspect of Oxygenta Pharmaceutical's performance is that it has consistently traded at its opening price of Rs. 108.64, indicating strong stability in its value. Additionally, the stock is currently trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a positive sign for investors.

In comparison to the Sensex, a benchmark index for the Indian stock market, Oxygenta Pharmaceutical has shown an impressive 1-year performance of 323.71%, while the Sensex has only grown by 25.67%. This further highlights the company's strong performance and potential for growth.

Overall, Oxygenta Pharmaceutical's recent achievement of hitting a 52-week high is a testament to its strong performance and potential in the pharmaceutical industry. With a "Hold" rating from MarketsMOJO and a consistently high trading value, the company is definitely one to watch in the market.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News